New York, New York – June 23, 2026: The International Insurance Society (IIS) is proud to announce the RGA Leaders of Tomorrow class of 2026, a distinguished global collective of emerging insurance executives. Select participants will share their insights at the 62ndGlobal Insurance Forum (GIF), taking place Nov. 15–16, 2026, at the Lloyd’s Building in London, UK.
Presented by RGA
GLP‑1 therapies are emerging as a critical area of focus for both population health and insurance risk. In this roundtable, RGA’s biometric experts examine the latest research and early evidence, unpacking what these therapies could mean in an evolving and uncertain landscape.
Key takeaways:
Presented by RGA
New results from the highly anticipated NHS-Galleri study show that the trial did not meet its primary endpoint of achieving a statistically significant reduction in combined Stage III and IV cancer diagnoses. While secondary findings offer more encouraging signals, particularly in detecting aggressive cancers, they warrant careful interpretation. RGA unpacks what these results mean for insurers today and what to watch as the landscape continues to evolve.
Presented by RGA
Long marked by late diagnosis and limited treatment, Alzheimer’s disease is now at a pivotal turning point. As breakthroughs emerge in early detection, prevention, and disease‑modifying therapies, could the global trajectory of Alzheimer’s finally be changing, and what might that mean for the decades ahead?
Presented by RGA
More than a decade of papers from the RGA Leaders of Tomorrow alumni reveal five enduring themes – digitalization, inclusion, talent, trust, and sustainability – consistently shaping the insurance industry’s strategic priorities and future trajectory.
Brittainy Rivers, COO & VP, Client Delivery, TAI, an RGA Company
Presented by RGA
Behavioral science techniques can significantly improve customer understanding of life insurance products and help reverse declining ownership rates, with RGA research offering practical strategies insurers can implement today.
Presented by RGA
Glucagon-like peptide 1 receptor agonists (GLP-1s) may be poised to become an integral part of treating a range of chronic diseases – from cardiovascular disease to cancer – and could improve all-cause mortality rates.
Presented by RGA
As the insurance industry evolves in response to technological advancements, shifting customer expectations, and emerging risks, leaders must adapt their skills and strategies to stay ahead—insights shared by Senan O’Loughlin, RGA.